Overview

Quetiapine Augmentation for Treatment-resistant PTSD

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the response of veterans with PTSD without an optimal response to paroxetine to quetiapine augmentation versus placebo.
Phase:
Phase 4
Details
Lead Sponsor:
VA Office of Research and Development
Collaborator:
AstraZeneca
Treatments:
Paroxetine
Quetiapine Fumarate